Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

576.36 -5.34 (-0.92%)
Streaming Delayed Price Updated: 3:23 PM EDT, Apr 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 245,398
Open 576.00
Bid (Size) 575.80 (40)
Ask (Size) 576.91 (160)
Prev. Close 581.69
Today's Range 571.91 - 582.45
52wk Range 266.98 - 607.89
Shares Outstanding 44,891,523
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
3 Market-Beating Stocks for Long-Term Investors
Stocks that outperform the market usually share key traits such as rising sales, expanding margins, and increasing returns on capital. The select few that ca... 
Via StockStory
Topics Energy
News headline image
United Therapeutics Surges 14% on Groundbreaking Tyvaso Phase 3 Results for IPF
In a landmark moment for respiratory medicine and biotechnology, United Therapeutics (NASDAQ:UTHR) announced late Monday, March 30, 2026, that its pivotal TETON-1 Phase 3 study for nebulized Tyvaso... 
Via MarketMinute

Performance

YTD
+16.0%
+16.0%
1 Month
+8.9%
+8.9%
3 Month
+14.4%
+14.4%
6 Month
+28.4%
+28.4%
1 Year
+106.1%
+106.1%

More News

Read More
Chips Down, Ackman Up: How Iran, the Fed, and a Viral Post Defined Monday's Market ↗
Via Chartmill
Topics Economy
News headline image
Why United Therapeutics (UTHR) Stock Is Up Today
Via StockStory
United Therapeutics Corp. (NASDAQ:UTHR) Emerges as a Peter Lynch-Style GARP Candidate ↗
Via Chartmill
United Therapeutics Corp (NASDAQ:UTHR) Emerges as a Peter Lynch-Style GARP Candidate ↗
Via Chartmill
United Therapeutics Corp. (NASDAQ:UTHR) Reports Record Annual Revenue Despite Q4 Top-Line Miss ↗
Via Chartmill
Traders are paying attention to the gapping stocks in Monday's session. ↗
Via Chartmill
News headline image
United Therapeutics Corporation Announces TETON-1 Pivotal Study of Tyvaso® Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2
From United Therapeutics Corporation
Via Business Wire
News headline image
1 Surging Stock with Impressive Fundamentals and 2 That Underwhelm
Via StockStory
News headline image
Therapeutics Stocks Q4 In Review: United Therapeutics (NASDAQ:UTHR) Vs Peers
Via StockStory
Topics Artificial Intelligence
News headline image
2 Mid-Cap Stocks for Long-Term Investors and 1 We Avoid
Via StockStory
News headline image
1 Cash-Heavy Stock to Target This Week and 2 That Underwhelm
Via StockStory
Topics Firearms
News headline image
This Biotech Stock Surged 75% Last Quarter and Pulled a New $9 Million Investment ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Life Sciences Supplier Has Plunged 50% in a Year, but One Fund Bought Up $28 Million More in Stock ↗
Via The Motley Fool
Topics Regulatory Compliance Supply Chain
News headline image
United Therapeutics Corporation Announces Full Results of TETON-2 Phase 3 Clinical Trial Published in The New England Journal of Medicine
From United Therapeutics Corporation
Via Business Wire
News headline image
Winners And Losers Of Q4: Biogen (NASDAQ:BIIB) Vs The Rest Of The Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
News headline image
United Therapeutics Corporation Announces $2 Billion Stock Repurchase Authorization and Enters into $1.5 Billion Accelerated Share Repurchase Program
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation to Present at the Leerink Global Healthcare Conference
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy
From United Therapeutics Corporation
Via Business Wire
News headline image
2 Cash-Producing Stocks to Keep an Eye On and 1 That Underwhelm
Via StockStory
News headline image
Why United Therapeutics (UTHR) Shares Are Sliding Today
Via StockStory
Topics Earnings
News headline image
The Moonshot Medicine: United Therapeutics Surges on Record Earnings and TreSMI Breakthrough
Via Finterra
Topics Earnings Economy Intellectual Property
News headline image
United Therapeutics (UTHR) Deep Dive: Strong Q4 and the ‘Inhalation Evolution’
Via Finterra
Topics Artificial Intelligence Economy Intellectual Property
News headline image
MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ ↗
Via Stocktwits

Frequently Asked Questions

Is United Therapeutics Corporation - Common Stock publicly traded?
Yes, United Therapeutics Corporation - Common Stock is publicly traded.
What exchange does United Therapeutics Corporation - Common Stock trade on?
United Therapeutics Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for United Therapeutics Corporation - Common Stock?
The ticker symbol for United Therapeutics Corporation - Common Stock is UTHR on the Nasdaq Stock Market
What is the current price of United Therapeutics Corporation - Common Stock?
The current price of United Therapeutics Corporation - Common Stock is 576.36
When was United Therapeutics Corporation - Common Stock last traded?
The last trade of United Therapeutics Corporation - Common Stock was at 04/09/26 03:23 PM ET
What is the market capitalization of United Therapeutics Corporation - Common Stock?
The market capitalization of United Therapeutics Corporation - Common Stock is 25.87B
How many shares of United Therapeutics Corporation - Common Stock are outstanding?
United Therapeutics Corporation - Common Stock has 26B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.